CHCHD2

Across TCGA pan-cancer cohorts, CHCHD2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CHCHD2 data layer compared with 24 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher CHCHD2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated CHCHD2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

CCRCC, HNSC, and UCEC are the cancer types where CHCHD2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	All	0.568	0.917	<.001	82	view →
HNSC	DFS	Median	All	0.540	0.729	.010	16	view →
UCEC	DFS	Tertile	II,III,IV	1.000	0.529	.008	12	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CHCHD2–CCRCC (DFS)

Open the CCRCC breakdown →